No abstract

S y n t h e s i s o f P o l y m e r -B o u n d 3 -N , N -( D i m e t h y l a m i n o ) -2 -i s o c y a n o a c r y l a t e Abstract: The synthesis of resin-bound 3-N,N-(dimethylamino)-2-isocyanoacrylate is described. This bifunctional reagent can be used for the synthesis of thiazoles via a multicomponent reaction. Several examples are reported.

IntroductionMultiple myeloma is still incurable in most cases. Polyclonal anti T lymphocyte globulins (ATG) have been reported to kill human myeloma cells in vitro and in mouse models.MethodsAnti-human-myeloma globulins (AMG) were produced by immunizing rabbits with human myeloma cell lines RPMI-8226 (AMG-8226) or KMS-12-BM (AMG-12-BM). Cytotoxicity of the polyclonal antibodies was analyzed in vitro and in a xenograft NOD-SCID mouse model.ResultsBoth AMG had stronger cytotoxicity against myeloma cells compared to ATG. In primary T cells, AMG-8226 showed greater complement-dependent cytotoxicity (CDC) than ATG, whereas complement-independent cytotoxicity did not differ. Effects on non-hematopoietic cell lines were also similar. Competitive blocking assays revealed fourfold more antibodies against CD38 in AMG-8226 compared to ATG. Low concentrations of AMG-8226 and ATG increased ADCC. At higher concentrations, ATG inhibited ADCC more potently than AMG-8226. Combinations of ATG and AMG-8226 with melphalan or bortezomib showed additive to synergistic cytotoxicity on myeloma cells. The cytotoxic effects of AMG and ATG were confirmed in the xenograft NOD-SCID mouse model.ConclusionOur data show more potent antimyeloma effects of AMG compared to ATG. These results lay the ground for the development of polyclonal antibodies for the treatment of multiple myeloma.

Thiazole derivatives Thiazole derivatives R 0260 Convergent Multicomponent Assembly of 2-Acyloxymethyl Thiazoles. -A novel three-component reaction of acrylate (I), thiocarboxylic acids and aldehydes is described. However, the yields of the biologically interesting 2-acyloxymethyl thiazoles (IV) are only low to moderate. -(HENKEL, B.; BECK, B.; WESTNER, B.; MEJAT, B.; DOEMLING*, A.; Tetrahedron Lett. 44 (2003) 50, 8947-8950;